EyeGene Inc. | |
Stock Exchange | Korea Exchange |
EPS |
KRW856 |
Market Cap |
KRW261.64 B |
Shares Outstanding |
10.99 M |
Public Float |
9.41 M |
Address |
Unit 910, Gangseo Han-gang Zai B Seoul SL 07528 Korea, Republic Of |
Employees | - |
Website | http://www.eyegene.co.kr |
Updated | 09/14/2018 |
Eyegene, Inc. engages in the research and development of pharmaceutical products. Its products include curing technologies and vaccines for diabetic retinopathy, decubitus ulcer, cervical cancer, and adjuvant immunotherapy. The company was founded on June 23, 2000 and is headquartered in Seoul, South Korea. |